参考文献/References:
[1] Lamirault G ,Artifoni M,Daniel M,et al. Resistant hypertension: novel insights[J]. Curr Hypertens Rev,2020,16(1):61-72.
[2] Yoon M,You SC,Oh J,et al. Prevalence and prognosis of refractory hypertension diagnosed using ambulatory blood pressure measurements[J]. Hypertens Res,2022,45(8):1353-1362.
[3] 李月平,卢成志,蒋雄京,等. 经皮去肾神经术治疗高血压中国专家科学声明[J]. 中国介入心脏病学杂志,2023,31(12):881-893.
[4] Barbato E,Azizi M,Schmieder RE,et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)[J]. Eur Heart J,2023,44(15):1313-1330.
[5] Zeijen VJM ,Kroon AA,van den Born BH,et al. The position of renal denervation in treatment of hypertension: an expert consensus statement[J]. Neth Heart J,2023,31(1):3-11.
[6] Wang TD ,Chiang CE,Chao TH,et al. 2022 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension[J]. Acta Cardiol Sin,2022,38(3):225-325.
[7] Chia YC,Wan Ahmad WA,Fong AYY,et al. 2022 Malaysian Working Group Consensus Statement on Renal Denervation for management of arterial hypertension[J]. Hypertens Res,2022,45(7):1111-1122.
[8] Kario K ,Kim B,Aoki J,et al. Renal denervation in Asia[J]. Hypertension,2020,75(3):590-602.
[9] Foss JD,Fink GD,Osborn JW. Differential role of afferent and efferent renal nerves in the maintenance of early- and late-phase Dahl S hypertension[J]. Am J Physiol Regul Integr Comp Physiol,2016,310(3):R262-R267.
[10] Dibona GF,Esler M. Translational medicine: the antihypertensive effect of renal denervation[J]. Am J Physiol Regul Integr Comp Physiol,2010,298(2):R245-R253.
[11] Kiuchi MG,Esler MD,Fink GD,et al. Renal denervation update from the international sympathetic nervous system summit: JACC State-of-the-Art Review[J]. J Am Coll Cardiol,2019,73(23):3006-3017.
[12] B?hm M,Mahfoud F,Townsend RR,et al. Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED,a randomized,sham-controlled,proof-of-concept trial[J]. Eur Heart J,2019,40(9):743-751.
[13] Gosse P,Cremer A,Pereira H,et al. Twenty-four-hour blood pressure monitoring to predict and assess impact of renal denervation: the DENERHTN study (renal denervation for hypertension)[J]. Hypertension,2017,69(3):494-500.
[14] Sharp A,Sanderson A,Hansell N,et al. Renal denervation for uncontrolled hypertension:a systematic review and meta-analysis examining multiple subgroups[J]. J Hypertens,2024,42(7):1133-1144.
[15] Bhatt DL,Kandzari DE,O’Neill WW,et al. A controlled trial of renal denervation for resistant hypertension[J]. N Engl J Med,2014,370(15):1393-1401.
[16] Mahfoud F,Mancia G,Schmieder R,et al. Renal denervation in high-risk patients with hypertension[J]. J Am Coll Cardiol,2020,75(23):2879-2888.
[17] Azizi M,Schmieder RE,Mahfoud F,et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO):a multicentre,international,single-blind,randomised,sham-controlled trial[J]. Lancet,2018,391(10137):2335-2345.
[18] Tsioufis CP,Papademetriou V,Dimitriadis KS,et al. Catheter-based renal denervation for resistant hypertension:twenty-four month results of the EnligHTN I first-in-human study using a multi-electrode ablation system[J]. Int J Cardiol,2015,201:345-350.
[19] Zuern CS,Eick C,Rizas KD,et al. Impaired cardiac baroreflex sensitivity predicts response to renal sympathetic denervation in patients with resistant hypertension[J]. J Am Coll Cardiol,2013,62(22):2124-2130.
[20] Id D,Bertog SC,Ziegler AK,et al. Predictors of blood pressure response:obesity is associated with a less pronounced treatment response after renal denervation[J]. Catheter Cardiovasc Interv,2016,87(1):e30-e38.
[21] Mahfoud F,Townsend RR,Kandzari DE,et al. Changes in plasma renin activity after renal artery sympathetic denervation[J]. J Am Coll Cardiol,2021,77(23):2909-2919.
[22] Okon T,Rohnert K,Stiermaier T,et al. Invasive aortic pulse wave velocity as a marker for arterial stiffness predicts outcome of renal sympathetic denervation[J]. EuroIntervention,2016,12(5):e684-e692.
[23] Fengler K,Rommel KP,Kriese W,et al. Assessment of arterial stiffness to predict blood pressure response to renal sympathetic denervation[J]. EuroIntervention,2022,18(8):e686-e694.
[24] Kannan A,Medina RI,Nagajothi N,et al. Renal sympathetic nervous system and the effects of denervation on renal arteries[J]. World J Cardiol,2014,6(8):814-823.
[25] Mahfoud F,Schlaich M,Kindermann I,et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension:a pilot study[J]. Circulation,2011,123(18):1940-1946.
[26] Verloop WL,Spiering W,Vink EE,et al. Denervation of the renal arteries in metabolic syndrome: the DREAMS-study[J]. Hypertension,2015,65(4):751-757.
[27] Koutra E,Dimitriadis K,Pyrpyris N,et al. Unravelling the effect of renal denervation on glucose homeostasis:more questions than answers?[J]. Acta Diabetol,2024,61(3):267-280.
[28] Ott C,Mahfoud F,Schmid A,et al. Improvement of albuminuria after renal denervation[J]. Int J Cardiol,2014,173(2):311-315.
[29] Bohm M,Mahfoud F,Ukena C,et al. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension[J]. Hypertension,2015,65(4):766-774.
[30] Veasey SC,Rosen IM. Obstructive sleep apnea in adults[J]. N Engl J Med,2019,380(15):1442-1449.
[31] Witkowski A,Prejbisz A,Florczak E,et al. Effects of renal sympathetic denervation on blood pressure,sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea[J]. Hypertension,2011,58(4):559-565.
[32] Korostovtseva LS,Ionov MV,Shcherbakova EA,et al. Progression of obstructive sleep apnoea after renal denervation is not associated with hypertension exaggeration[J]. BMC Pulm Med,2023,23(1):467.
[33] Kiuchi MG,Chen S,Villacorta H,et al. Renal denervation as a synergistic tool for the treatment of polymorphic ventricular ectopic beats:a case report[J]. Medicine (Baltimore),2020,99(29):e21098.
[34] Linz D,Mancia G,Mahfoud F,et al. Renal artery denervation for treatment of patients with self-reported obstructive sleep apnea and resistant hypertension: results from the Global SYMPLICITY Registry[J]. J Hypertens,2017,35(1):148-153.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(10):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(10):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(10):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(10):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(10):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(10):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(10):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(10):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(10):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
[11]李昱熙 张震 余静 蒋雄京.去肾神经治疗高血压的临床前景和探索方向[J].心血管病学进展,2024,(10):865.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.001]
LI YuxiZHANG ZhenYU JingJIANG Xiongjing.Future of Renal Denervation on Hypertension Therapy[J].Advances in Cardiovascular Diseases,2024,(10):865.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.001]
[12]陈晓平,左祥浩,叶涛,等.当前经导管去肾神经术治疗高血压面临的挑战[J].心血管病学进展,2024,(10):870.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.002]
CHEN Xiaoping,ZUO Xianghao,YE Tao,et al.Current Challenges of Transcatheter Renal Denervation in the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2024,(10):870.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.002]
[13]亢园园 罗淞元 许建忠 罗建方 卢成志.当前不同去肾神经术的特点和存在的问题[J].心血管病学进展,2024,(10):875.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.003]
KANG yuanyuan,LUO Songyuan,XU Jianzhong,et al.The Mechanisms and Future Challenges of Different Renal Denervation Therapy[J].Advances in Cardiovascular Diseases,2024,(10):875.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.003]
[14]王沛坚 陈威 董徽 马为.中国自主研发RDN器械治疗高血压临床试验数据的特色[J].心血管病学进展,2024,(10):880.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.004]
WANG Peijian,CHEN Wei,DONG Hui,et al.Characteristics of Clinical Trial Data of RDN Devices Independently Developed in China[J].Advances in Cardiovascular Diseases,2024,(10):880.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.004]
[15]董一飞 张毅 李燕 贾楠.经皮去肾神经术治疗高血压的临床获益：证据和争议[J].心血管病学进展,2024,(10):890.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.006]
DONG Yifei,ZHANG Yi,LI Yan,et al.Clinical Benefit of Renal Denervation In the Treatment of Hypertension:Evidence And Controversy[J].Advances in Cardiovascular Diseases,2024,(10):890.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.006]